On Sunday, April 20th 2025, starting 8:30am GMT, there will be maintenance work that will involve the website being unavailable during parts of the day. We apologize for any inconvenience this may cause and appreciate your understanding.
We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- The need for new antibiotics
- Decrease in number of new classes of antibiotics
- Why are so few antibiotics reaching the market?
- Companies leave the antibiotic research arena
- Targets
- Targeting bacterial molecules (genomics)
- Identifying a bacteria-specific essential gene
- Inhibition of essential gene product activity
- Kill of bacteria by inhibitor
- Problems with the genomic approach
- Bacteriophages
- Bacteriophage therapy
- Problems with bacteriophage therapy
- Targeting whole bacteria
- Multiplying bacteria as a target
- Non-culturable bacteria as a target
- Non-multiplying bacteria as a target
- Diseases with non-multiplying persistent bacteria
- Bacterial endocarditis
- Catheter infections (biofilms)
- Prosthesis infections (biofilms)
- Antibiotics and non-multiplying organisms
- Consequences of non-multiplying bacteria survival
- Methods for new antibiotics
- Helperby therapeutics
- Potential advantages of new antibiotics
- Non-multiplying bacteria - obstacles
- Many different subpopulations
- Fewer molecular targets
- Low penetration, high efflux
- High local concentration of bacteria
- Standardisation
- Minimum stationary-cidal concentration
- Minimum dormicidal concentration
- Conclusion
Topics Covered
- Urgent need for new antibiotics
- Why are so few antibiotics reaching the market
- Pharmaceutical companies leaving the research arena
- Targets
- Bacterial molecules (genomics)
- Problems with the genomic approach
- Bacteriophage
- Treatments and problems with bacteriophages
- Whole bacteria
- Conventional multiplying bacteria
- Non-culturable bacteria
- Non-multiplying bacteria
- Tuberculosis, bacterial endocarditis, catheter infections and prosthesis infections
- Ways of making new antibiotics against whole live bacteria
- Potential advantages and problems of making new antibiotics which kill non-multiplying and multiplying bacteria
- Standardization
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Coates, A. (2009, December 31). Overcoming resistance through novel drug targets [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved April 15, 2025, from https://doi.org/10.69645/MGBK1607.Export Citation (RIS)
Publication History
- Published on December 31, 2009
Financial Disclosures
- Prof. Anthony Coates has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.